PF-04418948

Research use only, not for human use.

PF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM.

PF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM; attenuates the butaprost-induced cutaneous blood flow response in rats; orally active.(In Vitro):PF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP.(In Vivo):PF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response.

PF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP. Cell Viability Assay Cell Line:CHO cells Concentration:2 μM Incubation Time:90 min Result:Inhibited prostaglandin E2 (PGE2)-induced increase in cAMP in cells expressing EP2 receptors with a functional KB value of 1.8 nM.

PF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response. Animal Model:Sprague Dawley rats Dosage:1, 3, and 10 mg/kg Administration:Oral gavage; 1, 3, and 10 mg/kg; once Result:Reduced the peak and AUC butaprost-induced cutaneous blood flow response in a dose-dependent fashion.

——

GPCR/G Protein

Prostaglandin Receptor

PGE2

Other Indications

Other Disease

1078166-57-0

409.407

C23H20FNO5

>98% (HPLC)

10 mM in DMSO

COC1=CC2=C(C=C1)C=C(C=C2)OCC3(CN(C3)C(=O)C4=CC=C(C=C4)F)C(=O)O

3-Azetidinecarboxylic acid, 1-(4-fluorobenzoyl)-3-[[(6-methoxy-2-naphthalenyl)oxy]methyl]-

(-20℃)

With Ice Pack

≥ 2 years